Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2006 Apr 10:5:9.
doi: 10.1186/1475-2840-5-9.

Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance

Isabella Schmoelzer  1 , Thomas C Wascher
Affiliations
Randomized Controlled Trial

Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance

Isabella Schmoelzer et al. Cardiovasc Diabetol. .

Abstract

Background: Impaired glucose tolerance (IGT) is associated with increased cardiovascular risk. The pathophysiological mechanisms linking post-challenge hyperglycemia to accelerated atherosclerosis, however remain to be elucidated.

Methods: A prospective, open, randomised, cross-over study was performed to investigate the effect of 2 mg repaglinide on hyperglycemia and endothelial function during an oral glucose tolerance test (75 g glucose) in 12 subjects with diagnosed IGT. Blood samples for determination of plasma glucose were drawn fasting, 1 and 2 hours after glucose ingestion. Endothelial function was assessed by measuring flow-mediated dilatation (FMD) of the brachial artery with high-resolution ultrasound.

Results: Administration of repaglinide resulted in a significant reduction of plasma glucose at 2 hours (172.8+/-48.4 vs. 138.3+/-41.2 mg/dl; p < 0.001). The flow-mediated dilatation (FMD) 2 hours after the glucose-load was significantly reduced in comparison to fasting in the control group (6.21+/-2.69 vs. 7.98+/-2.24 %; p = 0.028), whereas after theadministration of repaglinide the FMD was not significantly different to fasting values (7.24+/-2.57 vs. 8.18+/-2.93 %; p = n.s.). Linear and logistic regression analysis revealed that only the change of glucose was significantly correlated to the change of FMD observed (p < 0.001). Regression analysis after grouping for treatment and time confirmed the strong negative association of the changes of plasma glucose and FMD and indicate that the effect of repaglinide observed is based on the reduction glycemia.

Conclusion: In subjects with IGT, the endothelial dysfunction observed after a glucose challenge is related to the extent of hyperglycemia. Reduction of hyperglycemia by repaglinide reduces endothelial dysfunction in a glucose dependent manner.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Glucose and FMD Association between the change of glucose as well as the change of FMD in the study population grouped according to time and treatment (error bars represent standard deviation)
See this image and copyright information in PMC

References

    1. Qiao Q, Tuomilehto , Borch-Johnson K. Postchallenge hyperglycemia is associated with premature death and macrovascular complications. Diabetologia. 2003;46:M17–M21. - PubMed
    1. The Decode Study Group Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The Lancet. 1999;354:617–621. doi: 10.1016/S0140-6736(98)12131-1. - DOI - PubMed
    1. Celermajer DS. Endothelial dysfunction: does it matter? Is it reversible? JACC. 1997;30:325–333. - PubMed
    1. Schaechinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long term outcome of coronary heart disease. Circulation. 2000;101:1899–1906. - PubMed
    1. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstemann U, Munzel T. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 2001;88:14–22. - PubMed

Publication types

MeSH terms